Daiichi Sankyo's Pfaffenhofen site in Germany.

Dai­ichi Sankyo in­vests $1B to bulk out Ger­man site for can­cer AD­Cs 

Dai­ichi Sankyo is pour­ing €1 bil­lion ($1.07 bil­lion) in­to a Ger­man fa­cil­i­ty in part to ex­pand its ca­pac­i­ty for an­ti­body-drug con­ju­gate man­u­fac­tur­ing. The first part of the ex­pan­sion be­came op­er­a­tional last month, a com­pa­ny spokesper­son told End­points News.

The fa­cil­i­ty is in Pfaf­fen­hofen an der Ilm, which is a 40-minute dri­ve north of Mu­nich. The Japan­ese phar­ma will build a new lab for can­cer AD­Cs that will be fin­ished by 2026 in ad­di­tion to bol­ster­ing car­dio­vas­cu­lar dis­ease as­set pro­duc­tion. There is “in­creased glob­al de­mand for ADC can­cer ther­a­pies,” added Dai­ichi Eu­rope site man­ag­er Matthias Kühn in the press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.